Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Exact Therapeutics AS's Enterprise Value is kr58.40 Mil.
Exact Therapeutics AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-72.31 Mil. Therefore, Exact Therapeutics AS's EV-to-FCF for today is -0.81.
The historical rank and industry rank for Exact Therapeutics AS's EV-to-FCF or its related term are showing as below:
OSL:EXTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.8 Med: 0 Max: 0
Current: -0.8
OSL:EXTX's EV-to-FCF is ranked worse than 100% of 338
companies
in the Biotechnology industry
Industry Median: 15.02
vs OSL:EXTX: -0.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exact Therapeutics AS (OSL:EXTX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exact Therapeutics AS's PE Ratio (TTM) for today is calculated as:
Exact Therapeutics AS's share price for today is kr0.73.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-1.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:EXTX vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Exact Therapeutics AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Therapeutics AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Exact Therapeutics AS's EV-to-FCF falls into.
Exact Therapeutics AS's current Enterprise Value is kr58.40 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-72.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Therapeutics AS (OSL:EXTX) has a EV-to-FCF of -0.81 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Exact Therapeutics AS and its competitors. According to the industry distribution chart, Exact Therapeutics AS ranks #999999 out of 338 companies in the Biotechnology industry.
Is Exact Therapeutics AS's EV-to-FCF too high?
Exact Therapeutics AS's current EV-to-FCF is -0.81. Based on the distribution chart, Exact Therapeutics AS ranks #999999 out of 338 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Exact Therapeutics AS has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Exact Therapeutics AS ranks #999999 out of 338 companies for EV-to-FCF. This places Exact Therapeutics AS in the lower half of its industry. The industry median EV-to-FCF is 15.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.02, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Exact Therapeutics AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exact Therapeutics AS's current EV-to-FCF is -0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (OSL:EXTX) has a current EV-to-FCF of -0.81. The current EV-to-FCF is -0.81. Exact Therapeutics AS's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Exact Therapeutics AS (OSL:EXTX), the current EV-to-FCF is -0.81 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
21GF Score
Get the complete analysis for OSL:EXTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:EXTX has been successfully added to your 
